Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.

Fuller NM, Davies NG, McHugh TD, Knight GM

DOI: 10.3389/ftubr.2025.1667354
Published: 2025
Container: Frontiers in tuberculosis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/ftubr.2025.1667354,
  title = {Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.},
  author = {Fuller NM and Davies NG and McHugh TD and Knight GM},
  year = {2025},
  journal = {Frontiers in tuberculosis},
  doi = {10.3389/ftubr.2025.1667354},
  url = {https://doi.org/10.3389/ftubr.2025.1667354}
}

RIS

TY  - JOUR
TI  - Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.
AU  - Fuller NM
AU  - Davies NG
AU  - McHugh TD
AU  - Knight GM
PY  - 2025
JO  - Frontiers in tuberculosis
DO  - 10.3389/ftubr.2025.1667354
UR  - https://doi.org/10.3389/ftubr.2025.1667354
ER  -

APA

NM, F., NG, D., TD, M., & GM, K. (2025). Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.. Frontiers in tuberculosis. https://doi.org/10.3389/ftubr.2025.1667354

Source records

pubmed · retrieved 2026-09-25T23:06:20.090Z